{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:47:28Z","timestamp":1775227648031,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Innovation Challenge Fund"},{"name":"Oxford Biomedical Research Centre"},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12891-018-1949-2","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T08:06:30Z","timestamp":1516867590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["What do we know about managing Dupuytren\u2019s disease cost-effectively?"],"prefix":"10.1186","volume":"19","author":[{"given":"Melina","family":"Dritsaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Rivero-Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Ball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagdeep","family":"Nanchahal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,25]]},"reference":[{"issue":"3","key":"1949_CR1","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s11552-008-9160-9","volume":"4","author":"S Hindocha","year":"2009","unstructured":"Hindocha S, McGrouther DA, Bayat A. Epidemiological evaluation of Dupuytren's disease incidence and prevalence rates in relation to etiology. Hand (NY). 2009;4(3):256\u201369.","journal-title":"Hand (NY)"},{"issue":"90","key":"1949_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19900","volume":"19","author":"M Brazzelli","year":"2015","unstructured":"Brazzelli M, Cruickshank M, Tassie E, McNamee P, Robertson C, Elders A, Fraser C, Hernandez R, Lawrie D, Ramsay C. Collagenase clostridium histolyticum for the treatment of Dupuytren's contracture: systematic review and economic evaluation. Health Technol Assess. 2015;19(90):1\u2013202.","journal-title":"Health Technol Assess"},{"issue":"7538","key":"1949_CR3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1136\/bmj.332.7538.397","volume":"332","author":"WA Townley","year":"2006","unstructured":"Townley WA, Baker R, Sheppard N, Grobbelaar AO. Dupuytren\u2019s contracture unfolded. BMJ. 2006;332(7538):397\u2013400.","journal-title":"BMJ"},{"issue":"1","key":"1949_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/030097401750065292","volume":"30","author":"KG Gudmundsson","year":"2001","unstructured":"Gudmundsson KG, Arngrimsson R, Jonsson T. Eighteen years follow-up study of the clinical manifestations and progression of Dupuytren's disease. Scand J Rheumatol. 2001;30(1):31\u20134.","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"1949_CR5","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jhsa.2005.03.005","volume":"30","author":"RM Reilly","year":"2005","unstructured":"Reilly RM, Stern PJ, Goldfarb CA. A retrospective review of the management of Dupuytren's nodules. J Hand Surg Am. 2005;30(5):1014\u20138.","journal-title":"J Hand Surg Am."},{"issue":"6","key":"1949_CR6","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jhsa.2013.03.036","volume":"38","author":"J Wilburn","year":"2013","unstructured":"Wilburn J, McKenna SP, Perry-Hinsley D, Bayat A. The impact of dupuytren disease on patient activity and quality of life. J Hand Surg Am. 2013;38(6):1209\u201314.","journal-title":"J Hand Surg Am"},{"issue":"2","key":"1949_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.bjps.2014.10.011","volume":"68","author":"E Bebbington","year":"2015","unstructured":"Bebbington E, Furniss D. Linear regression analysis of hospital episode statistics predicts a large increase in demand for elective hand surgery in England. J Plast Reconstr Aesthet Surg. 2015;68(2):243\u201351.","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"1","key":"1949_CR8","first-page":"3","volume":"38","author":"BA MD","year":"2006","unstructured":"MD BA. Management of Dupuytren\u2019s disease \u2013 clear advice for an elusive solution. Ann R Coll Surg. 2006;38(1):3\u20138.","journal-title":"Ann R Coll Surg"},{"key":"1949_CR9","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1056\/NEJMoa0810866","volume":"361","author":"LC Hurst","year":"2009","unstructured":"Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FTD, Meals RA, et al. Injectable collagenase clostridium histolyticum for Dupuytren\u2019s contracture. N Engl J Med. 2009;361:968\u201379.","journal-title":"N Engl J Med"},{"issue":"12","key":"1949_CR10","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/j.jhsa.2010.08.007","volume":"35","author":"D Gilpin","year":"2010","unstructured":"Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagenase clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease. J Hand Surg Am. 2010;35(12):2027\u201338. e1","journal-title":"J Hand Surg Am."},{"key":"1949_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/PRS.0b013e31823aea95","volume":"129","author":"AL van Rijssen","year":"2012","unstructured":"van Rijssen AL, ter Linden H, Werker PM. 5-year results of randomized clinical trial on treatment in Dupuytren's disease: percutaneous needle fasciotomy versus limited fasciectomy. Plast Reconstr Surg. 2012;129:469\u201377.","journal-title":"Plast Reconstr Surg"},{"key":"1949_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jhsa.2012.09.028","volume":"38","author":"CA Peimer","year":"2013","unstructured":"Peimer CA, Blazar P, Coleman S, et al. Dupuytren contracture recurrence following treatment with Collagenase clostridium Histolyticum (CORDLESS study): 3-year data. J Hand Surg. 2013;38:12\u201322.","journal-title":"J Hand Surg"},{"key":"1949_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12891-016-1200-y","volume":"17","author":"C Ball","year":"2016","unstructured":"Ball C, Izadi D, Verjee LV, Chan J, Nanchahal J. Systematic review of non-surgical treatments for early Dupuytren\u2019s disease. BMC Musculoskelet Disord. 2016;17:345.","journal-title":"BMC Musculoskelet Disord"},{"issue":"10","key":"1949_CR14","doi-asserted-by":"publisher","first-page":"E928","DOI":"10.1073\/pnas.1301100110","volume":"110","author":"LS Verjee","year":"2013","unstructured":"Verjee LS, Verhoekx JS, Chan JKK, et al. Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target. PNAS. 2013;110(10):E928\u2013E37.","journal-title":"PNAS"},{"issue":"113","key":"1949_CR15","doi-asserted-by":"publisher","first-page":"7291","DOI":"10.1073\/pnas.1607896113","volume":"5","author":"J Nanchahal","year":"2016","unstructured":"Nanchahal J, Hinz B. Strategies to overcome the hurdles to treat fibrosis, a major unmet clinical need. PNAS. 2016;5(113):7291\u20133.","journal-title":"PNAS"},{"issue":"2","key":"1949_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, Force I. Consolidated health economic evaluation reporting standards (CHEERS)--explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231\u201350.","journal-title":"Value Health"},{"key":"1949_CR17","doi-asserted-by":"publisher","first-page":"c869","DOI":"10.1136\/bmj.c869","volume":"340","author":"D Moher","year":"2010","unstructured":"Moher D, Hopewell S, Schulz K, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.","journal-title":"BMJ"},{"key":"1949_CR18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/1471-2288-12-168","volume":"12","author":"C Bennett","year":"2012","unstructured":"Bennett C, Manuel DG. Reporting guidelines for modelling studies. BMC Med Res Methodol. 2012;12:168.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"1949_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00019053-200624040-00006","volume":"24","author":"Z Philips","year":"2006","unstructured":"Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment. A review and consolidation of quality assessment. PharmacoEconomics. 2006;24(4):355\u201371.","journal-title":"PharmacoEconomics"},{"issue":"11","key":"1949_CR20","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.jhsa.2011.08.004","volume":"36","author":"NC Chen","year":"2011","unstructured":"Chen NC, Shauver MJ, Chung KC. Cost-effectiveness of open partial fasciectomy, needle aponeurotomy, and collagenase injection for dupuytren contracture. J Hand Surg Am. 2011;36(11):1826\u201334. e32","journal-title":"J Hand Surg Am."},{"issue":"3","key":"1949_CR21","doi-asserted-by":"publisher","first-page":"A128","DOI":"10.1016\/j.jval.2011.02.714","volume":"14","author":"C Sau","year":"2011","unstructured":"Sau C, Bounthavong M, Tran JN, Wilson RL. Cost-utility analysis of collagenase clostridium histolyticum, limited fasciectomy, and percutaneous needle fasciotomy in dupuytren's contracture. Value Health. 2011;14(3):A128.","journal-title":"Value Health"},{"issue":"8","key":"1949_CR22","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1302\/0301-620X.95B8.31822","volume":"95-B","author":"H Baltzer","year":"2013","unstructured":"Baltzer H, Binhammer PA. Cost-effectiveness in the management of Dupuytren's contracture. A Canadian cost-utility analysis of current and future management strategies. Bone Joint J. 2013;95-B(8):1094\u2013100.","journal-title":"Bone Joint J"},{"key":"1949_CR23","unstructured":"(NICE) NIfHaCE. Guide to the Methods of Technolog Appraisal. London: NICE. 2013;URL: \n                    http:\/\/publications.nice.org.uk\/guide-to-the-methods-oftechnology-appraisal-2013-pmg9\n                    \n                  ."},{"key":"1949_CR24","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3109\/17453674.2013.865097","volume":"84","author":"NY Gu","year":"2013","unstructured":"Gu NY, Botteman MF, Gerber RA, Ji X, Postema R, Wan Y, et al. Eliciting health state utilities for Dupuytren\u2019s contracture using a discrete choice experiment. Acta Orthop. 2013;84:571\u20138.","journal-title":"Acta Orthop"},{"issue":"2","key":"1949_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1046\/j.1524-4733.1998.120131.x","volume":"1","author":"MT Halpern","year":"1998","unstructured":"Halpern MT, Luce BR, Brown RE, et al. Health and economic outcomes modeling practices: a suggested framework. Value Health. 1998;1(2):131\u201347.","journal-title":"Value Health"},{"key":"1949_CR26","unstructured":"Excellence NIfHaC. Social Value Judgments. Principles for the development of NICE guidance. London: National Institute for Health and Clinical Excellence; 2008."},{"issue":"6","key":"1949_CR27","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","volume":"15","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM modeling good research practices task Force-1. Value Health. 2012;15(6):796\u2013803.","journal-title":"Value Health"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-018-1949-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T19:27:14Z","timestamp":1548358034000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-018-1949-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,25]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1949"],"URL":"https:\/\/doi.org\/10.1186\/s12891-018-1949-2","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,25]]},"assertion":[{"value":"18 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All named authors declare that they have no competing interest with respect to the research, authorship, and\/or publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"34"}}